#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement


Authors: Robert;  Hegele;  Jan Borén;  Henry N Ginsberg;  Marcello Arca;  Maurizio Averna;  Christoph J Binder;  Laura Calabresi;  M. John Chapman;  Marina Cuchel;  Arnold Von Eckardstein;  Ruth Frikke-Schmidt;  Daniel Gaudet;  G. Kees Hovingh;  Florian Kronenberg;  Dieter Lütjohann;  Klaus G Parhofer;  Frederick J Raal;  Kausik K Ray;  Alan T Remaley;  Jane K Stock;  Erik S Stroes;  Lale Tokgözo Lu;  Alberico L Catapano
Authors‘ workplace: Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands (Prof G K Hovingh MD, Prof E S Stroes MD) ;  Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (Prof J Borén MD) ;  and Lipid Clinic, Chicoutimi Hospital, Chicoutimi, QC, Canada (Prof D Gaudet) ;  European Atherosclerosis Society, Gothenburg, Sweden (J K Stock PhD) ;  Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy (Prof A L Catapano PhD) ;  Medizinische Klinik IV-Grosshadern, University of Munich, Munich, Germany (Prof K G Parhofer MD) ;  Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK (Prof K K Ray MD) ;  National Institute for Health and Medical Research (INSERM), Sorbonne University and Pitié-Salpétrière University Hospital, Paris, France (Prof M J Chapman DSc) ;  Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (M Cuchel MD) ;  Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria (Prof C J Binder MD) ;  Centro Grossi Paoletti, Dipartimento di Scienze Farmacologichee Biomolecolari, Università degli Studi di Milano, Milan, Italy (Prof L Calabresi PhD) ;  Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo, Palermo, Italy (Prof M Averna MD) ;  Department of Internal Medicine and Allied Sciences, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome, Italy (M Arca MD) ;  Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA (Prof H N Ginsberg MD) ;  Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria (Prof F Kronenberg MD) ;  Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland (Prof A von Eckardstein MD) ;  Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany (D Lütjohann PhD) ;  Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark (Prof R Frikke-Schmidt MD) ;  Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa (Prof F J Raal MD) ;  Department of Clinical Biochemistry, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark (Prof R Frikke-Schmidt) ;  Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA (Prof A T Remaley MD) ;  Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Université de Montréal, Montreal, QC, Canada (Prof D Gaudet MD) ;  Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey (Prof L Tokgözoğlu MD) ;  ECOGENE, Clinical and Translational Research Center (Prof D Gaudet) ;  and IRCCS MultiMedica, Milan, Italy (Prof A L Catapano) ;  Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (Prof R A Hegele MD)
Published in: AtheroRev 2021; 6(Supplementum 1): 3-18
Category: Guidelines

Overview

Sekvenování genomu a genové terapie jsou slibnými strategiemi, které by měly zkvalitnit péči o pacienty se vzácnými poruchami lipoproteinů a souvisejícími dyslipidemiemi. V praxi je však běžné „poddiagnostikování“ a nedostatečná léčba zejména z důvodu významné interindividuální variability v genetické příčině i výsledném fenotypu. Evropská společnost pro aterosklerózu tedy jmenovala pracovní skupinu, aby vypracovala praktická klinická doporučení zaměřená na pacienty s extrémními (nízkými nebo vysokými) plazmatickými koncentracemi cholesterolu v lipoproteinech o nízké hustotě, triglyceridů nebo cholesterolu v lipoproteinech o vysoké hustotě. Tato doporučení rovněž reflektují nedostatek kvalitních dat o prevalenci a důsledcích těchto onemocnění. Pro zlepšení opatření v péči o pacienty se vzácnými dyslipidemiemi jsou nutné rozsáhlejší registry.


Sources

1       Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015; 18: 906–14.

2       European Medicines Agency. Orphan designation: overview. https://www.ema.europa.eu/en/human-regulatory/overview/ orphan-designation-overview (accessed April 4, 2019).

3       Orphan Drug Act. Rare diseases act of 2002. https://www.govinfo. gov/content/pkg/PLAW-107publ280/html/PLAW-107publ280.htm (accessed April 4, 2019).

4       EURORDIS. Fact sheet. What is a rare disease? https://www. eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf (accessed April 9, 2019).

5       Boycott KM, Hartley T, Biesecker LG, et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell 2019; 177: 32–37.

6       Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol 2018; 29: 133–43.

7       Hegele RA, Ban MR, Cao H, McIntyre AD, Robinson JF, Wang J. Targeted next-generation sequencing in monogenic dyslipidemias. Curr Opin Lipidol 2015; 26: 103–13.

8       Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009; 10: 109–21.

9       Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478–90a.

10     Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers 2017; 3: 17093.

11     Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–57.

12     Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002; 359: 841–47.

13     Iacocca MA, Chora JR, Carrié A, et al. ClinVar database of global familial hypercholesterolemia-associated DNA variants. Hum Mutat 2018; 39: 1631–40.

14     Andersen LH, Miserez AR, Ahmad Z, Andersen RL. Familial defective apolipoprotein B-100: a review. J Clin Lipidol 2016; 10: 1297–302.

15     Dron JS, Hegele RA. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol 2017; 28: 161–69.

16     Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol 2016; 36: 2439–45.

17     Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol 2019; 16: 9–20.

18     Reiner Ž, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency—an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014; 235: 21–30.

19     Julius U. Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis 2018; 5: e27.

20     Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017; 5: 280–90.

21     Blom DJ, Averna MR, Meagher EA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation 2017; 136: 332–35.

22     Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res 2019; 124: 386–404.

23     Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377: 296–97.

24     Kidambi S, Patel SB. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. J Clin Pathol 2008; 61: 588–94.

25     Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015; 373: 1010–20.

26     Hooper AJ, Burnett JR. Update on primary hypobetalipoproteinemia. Curr Atheroscler Rep 2014; 16: 423.

27     Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci 2005; 42: 515–45.

28     Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis 2014; 37: 333–39.

29     Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161–68.

30     Parhofer KG, Barrett PH, Bier DM, Schonfeld G. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo. J Clin Invest 1992; 89: 1931–37.

31     Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol 1997; 17: 881–88.

32     Parhofer KG, Barrett PH, Aguilar-Salinas CA, Schonfeld G. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J Lipid Res 1996; 37: 844–52.

33     Levy E, Poinsot P, Spahis S. Chylomicron retention disease: genetics, biochemistry, and clinical spectrum. Curr Opin Lipidol 2019; 30: 134–39.

34     Minicocci I, Montali A, Robciuc M R, et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab 2012; 97: e1266–75.

35     Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363: 2220–27.

36     Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514–23.

37     Di Costanzo A, Di Leo E, Noto D, et al. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: a comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. J Clin Lipidol 2017; 11: 1234–42.

38     Brahm AJ, Hegele RA. Chylomicronaemia—current diagnosis and future therapies. Nat Rev Endocrinol 2015; 11: 352–62.

39     Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol 2019; 13: 80–88.

40     Dron JS, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep 2017; 19: 31.

41     Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol 2018; 12: 920–27.

42     Péterfy M. Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism. Biochim Biophys Acta 2012; 1821: 790–94.

43     Fong LG, Young SG, Beigneux AP, et al. GPIHBP1 and plasma triglyceride metabolism. Trends Endocrinol Metab 2016; 27: 455–69.

44     Iacocca MA, Dron JS, Hegele RA. Progress in finding pathogenic DNA copy number variations in dyslipidemia. Curr Opin Lipidol 2019; 30: 63–70.

45     Basel-Vanagaite L, Zevit N, Har Zahav A, et al. Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am J Hum Genet 2012; 90: 49–60.

46     Lee JH, Giannikopoulos P, Duncan SA, et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med 2011; 17: 812–15.

47     Rees MG, Raimondo A, Wang J, et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Genet 2014; 23: 5570–78.

48     Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia— differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis 2019; 283: 137–42.

49     Berberich AJ, Ziada A, Zou GY, Hegele RA. Conservative management in hypertriglyceridemia-associated pancreatitis. J Intern Med 2019; published online May 11. DOI:10.1111/joim.12925.

50     Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab 2012; 97: 2589–96.

51     Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J 2019; published online April 24. DOI:10.1093/eurheartj/ehz209.

52     Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology 2019; 51: 165–76.

53     Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P. The spectrum of type III hyperlipoproteinemia. J Clin Lipidol 2018; 12: 1383–89.

54     Pollin T, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322: 1702–05.

55     Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem 2018; 64: 1006–33.

56     Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

57     März W, Kleber ME, Scharnagl H, Speer T, et al. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol 2017; 106: 663–75.

58     Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432–48.

59     Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 2524–32.

60     Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572–-80.

61     Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed MA, Al-Aly Z. High density lipoprotein cholesterol and the risk of all-cause mortality among US veterans. Clin J Am Soc Nephrol 2016; 11: 1784–93.

62     Ko DT, Alter DA, Guo H, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART Study. J Am Coll Cardiol 2016; 68: 2073–83.

63     Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38: 2478–86.

64     Madsen CM, Varbo A, Tybjærg-Hansen A, Frikke-Schmidt R, Nordestgaard BG. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J 2018; 39: 1181–90.

65     Dron JS, Wang J, Low-Kam C, et al. Polygenic determinants in extremes of high-density lipoprotein cholesterol. J Lipid Res 2017; 58: 2162–70.

66     Geller AS, Polisecki EY, Diffenderfer MR, et al. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J Lipid Res 2018; 59: 2421–35.

67     Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic ABCA1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of ApoA-I. J Clin Invest 2005; 115: 1333–42.

68     Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006; 116: 1052–62.

69     Zhu X, Lee JY, Timmins JM, et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283: 22930–41.

70     Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905–19.

71     Fellin R, Manzato E. Lipoprotein-X fifty years after its original discovery. Nutr Metab Cardiovasc Dis 2019; 29: 4–8.

72     Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012; 222: 299–306.

73     Ossoli A, Neufeld EB, Thacker SG, et al. Lipoprotein X causes renal disease in LCAT deficiency. PLoS One 2016; 11: e0150083.

74     Imbasciati E, Paties C, Scarpioni L, Mihatsch MJ. Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Ultrastructural heterogeneity of glomerular changes. Am J Nephrol 1986; 6: 66–70.

75     Oldoni F, Baldassarre D, Castelnuovo S, et al. Complete and partial LCAT deficiency are differentially associated with atherosclerosis. Circulation 2018; 138: 1000–07.

76     Lu C, Zuo K, Lu Y, et al. Apolipoprotein A-1-related amyloidosis: 2 case reports and review of the literature. Medicine (Baltimore) 2017; 96: e8148.

77     Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet 2012; 8: e1003063.

78     Das M, Wilson CJ, Mei X, Wales TE, Engen JR, Gursky O. Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic? J Mol Biol 2016; 428: 449–62.

79     Santos RD, Asztalos BF, Martinez LR, Miname MH, Polisecki E, Schaefer EJ. Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. J Clin Lipidol 2008; 2: 237–47.

80     Tanaka S, Haketa A, Sakimoto T, Abe M. A case of apolipoprotein A-I deficiency due to carboxyl-terminal truncation. J Clin Lipidol 2018; 12: 511–14.

81     Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF. Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis 2016; 59: 97–106.

82     Hooper AJ, McCormick SPA, Hegele RA, Burnett JR. Clinical utility gene card for: Tangier disease. Eur J Hum Genet 2017; published online May 24. DOI:10.1038/ejhg.2017.72.

83     Muratsu J, Koseki M, Masuda D, et al. Accelerated atherogenicity in Tangier Disease. J Atheroscler Thromb 2018; 25: 1076–85.

84     Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107: 85–98.

85     Saeedi R, Li M, Frohlich J. A review on lecithin: cholesterol acyltransferase deficiency. Clin Biochem 2015; 48: 472–75.

86     Jonas A. Lecithin cholesterol acyltransferase. Biochem Biophys Acta 2000; 1529: 245–46.

87     Holleboom AG, Kuivenhoven JA, van Olden CC, et al. Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase. Atherosclerosis 2011; 216: 161–65.

88     Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol 2008; 102: 1341–47.

89     Kootte RS, Smits LP, van der Valk FM, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res 2015; 56: 703–12.

90     Aranda P, Valdivielso P, Pisciotta L, et al. Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol 2008; 69: 213–18.

91     Strom EH, Sund S, Reier-Nilsen M, Dorje C, Leren TP. Lecithin: cholesterol acyltransferase (LCAT) deficiency: renal lesions with early graft recurrence. Ultrastruct Pathol 2011; 35: 139–45.

92     Shamburek RD, Bakker-Arkema R, Shamburek AM, et al. Safety and tolerability of ACP-501, a recombinant human lecithin: cholesterol acyltransferase, in a phase 1 single-dose escalation study. Circ Res 2016; 118: 73–82.

93     Freeman LA, Demosky SJ Jr, Konaklieva M, et al. Lecithin: cholesterol acyltransferase activation by sulfhydryl-reactive small molecules: role of cysteine-31. J Pharmacol Exp Ther 2017; 362: 306–18.

94     Shamburek RD, Bakker-Arkema R, Auerbach BJ, et al. Familial lecithin: cholesterol acyltransferase deficiency: first-in-human treatment with enzyme replacement. J Clin Lipidol 2016; 10: 356–67.

95     Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323: 1234–38.

96     Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364: 136–45.

97     Brunham LR, Tietjen I, Bochem AE, et al. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin Genet 2011; 79: 575–81.

98     Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 2016; 351: 1166–71.

99     Tall AR, Rader DJ. Trials and tribulations of CETP Inhibitors.

Circ Res 2018; 122: 106–12.

100  Hegele RA, Little JA, Vezina C, et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics.

Arterioscler Thromb 1995; 13: 720–08.

101  Davignon J, Dufour R. Primary hyperlipidemias. Oxford: Clinical Publishing, 2007.

102  Genest J, Hegele RA, Bergeron J, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014; 30: 1471–81.

103  Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1: 40.

104  Sassolas A, Filippo M Di, Aggerbeck LP, Peretti N, Samson-Bouma ME. Anderson’s disease/chylomicron retention disease and mutations in the SAR1B gene, mutations in human genetic disease. London: IntechOpen, 2012.

105  Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113–20.

106  Ravesloot MJ, Bril H, Braamskamp MJ, Wiegman A, Wong Chung RP. The curious case of the orange coloured tonsils. Int J Ped Otorhinolaryngology 2014; 78: 2305–07.

Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#